DE69812602D1 - Antagonisten des vitronectin-rezeptors - Google Patents

Antagonisten des vitronectin-rezeptors

Info

Publication number
DE69812602D1
DE69812602D1 DE69812602T DE69812602T DE69812602D1 DE 69812602 D1 DE69812602 D1 DE 69812602D1 DE 69812602 T DE69812602 T DE 69812602T DE 69812602 T DE69812602 T DE 69812602T DE 69812602 D1 DE69812602 D1 DE 69812602D1
Authority
DE
Germany
Prior art keywords
receptor antagonists
vitronectin receptor
vitronectin
antagonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69812602T
Other languages
English (en)
Other versions
DE69812602T2 (de
Inventor
H Miller
E Bondinell
Wen Ku
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of DE69812602D1 publication Critical patent/DE69812602D1/de
Publication of DE69812602T2 publication Critical patent/DE69812602T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734Ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69812602T 1997-01-08 1998-01-08 Antagonisten des vitronectin-rezeptors Expired - Lifetime DE69812602T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3402697P 1997-01-08 1997-01-08
US34026P 1997-01-08
PCT/US1998/000490 WO1998030542A1 (en) 1997-01-08 1998-01-08 Vitronectin receptor antagonists

Publications (2)

Publication Number Publication Date
DE69812602D1 true DE69812602D1 (de) 2003-04-30
DE69812602T2 DE69812602T2 (de) 2004-02-19

Family

ID=21873846

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69812602T Expired - Lifetime DE69812602T2 (de) 1997-01-08 1998-01-08 Antagonisten des vitronectin-rezeptors

Country Status (30)

Country Link
US (2) US6069158A (de)
EP (1) EP0977735B1 (de)
JP (1) JP2001508067A (de)
KR (1) KR20000069941A (de)
CN (1) CN1249745A (de)
AP (1) AP9901597A0 (de)
AR (1) AR010873A1 (de)
AT (1) ATE235467T1 (de)
AU (1) AU729641B2 (de)
BG (1) BG103548A (de)
BR (1) BR9806852A (de)
CA (1) CA2276738A1 (de)
CO (1) CO4920232A1 (de)
DE (1) DE69812602T2 (de)
DZ (1) DZ2395A1 (de)
EA (1) EA199900630A1 (de)
ES (1) ES2196534T3 (de)
HU (1) HUP0001945A3 (de)
ID (1) ID23168A (de)
IL (1) IL130760A0 (de)
MA (1) MA26462A1 (de)
NO (1) NO993350L (de)
NZ (1) NZ336560A (de)
OA (1) OA11076A (de)
PE (1) PE44799A1 (de)
PL (1) PL334499A1 (de)
SK (1) SK92799A3 (de)
TR (1) TR199901575T2 (de)
WO (1) WO1998030542A1 (de)
ZA (1) ZA9896B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011626A1 (en) * 1997-09-04 1999-03-11 Smithkline Beecham Corporation Integrin receptor antagonists
US6576643B2 (en) 1997-09-19 2003-06-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
PE122699A1 (es) * 1997-09-19 2000-02-12 Smithkline Beecham Corp Antagonistas de receptores de vitronectina
CN1140511C (zh) 1998-04-09 2004-03-03 明治制果株式会社 作为整合素αvβ3拮抗剂的氨基哌啶衍生物
JP4240424B2 (ja) * 1998-10-23 2009-03-18 エルジー ディスプレイ カンパニー リミテッド エッチング剤及びこれを用いた電子機器用基板の製造方法
US6339083B1 (en) 1998-12-14 2002-01-15 Bayer Aktiengesellschaft Multiheterocyclic pharmAceuticals
CA2358855A1 (en) 1999-02-03 2000-08-10 Merck & Co., Inc. Benzazepine derivatives as alpha-v integrin receptor antagonists
DE19916837A1 (de) * 1999-04-14 2000-10-19 Merck Patent Gmbh Dibenzoazulenderivate
US6750219B1 (en) 1999-08-05 2004-06-15 Meiji Seika Kaisha, Ltd. Ω-amino-α-hydroxycarboxylic acid derivatives having integrin ανβ3 antagonistic activity
DE19936780A1 (de) 1999-08-09 2001-02-15 Basf Ag Neue Antagonisten von Integrinrezeptoren
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2004513953A (ja) * 2000-10-24 2004-05-13 メルク エンド カムパニー インコーポレーテッド ジベンズオキサゼピンαVインテグリン受容体アンタゴニスト
EP1381384B1 (de) 2001-04-24 2011-05-25 Merck Patent GmbH KOMBINATIONSTHERAPIE MIT ANTIANGIOGENEN MITTELN UND TNFalpha
CA2464472C (en) 2001-10-22 2014-01-07 The Scripps Research Institute Antibody targeting compounds
GB0215867D0 (en) * 2002-07-09 2002-08-14 Glaxosmithkline Spa Novel method and compounds
CN1964740A (zh) * 2004-04-02 2007-05-16 加利福尼亚大学董事会 治疗和预防与αVβ5整联蛋白有关的疾病的方法和组合物
AU2012216372B2 (en) * 2004-04-02 2015-01-22 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2006128689A2 (de) 2005-05-31 2006-12-07 Ralf Jochem Therapeutsche zusammensetzung zur vorbeugung und bekämpfung von knochenmetastasen
WO2007048127A2 (en) * 2005-10-20 2007-04-26 The Scripps Research Institute Fc labeling for immunostaining and immunotargeting
WO2007084670A2 (en) 2006-01-18 2007-07-26 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
KR20090108713A (ko) 2007-01-18 2009-10-16 메르크 파텐트 게엠베하 인테그린 리간드를 사용하는 암치료용 특이적 요법 및 의약
WO2009082437A2 (en) 2007-12-21 2009-07-02 Ligand Pharmaceuticals Incorporated Selective androgen receptor modulators (sarms) and uses thereof
EP2395992A2 (de) 2009-02-10 2011-12-21 The Scripps Research Institute Chemisch programmierte impfung
SG176103A1 (en) 2009-05-25 2011-12-29 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
KR101752515B1 (ko) 2009-07-24 2017-06-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Avb5 인테그린과 결부된 질환의 치료 및 예방을 위한 방법 및 조성물
MX2016015467A (es) 2014-05-30 2017-03-23 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de androgenos.
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794424A (fr) * 1972-01-24 1973-07-23 Science Union & Cie Nouveaux dibenzocycloheptenes, leur procede d'obtention et leur application comme medicament
US3906032A (en) * 1972-11-10 1975-09-16 Squibb & Sons Inc Dihydroxy-tetrahydronaphthyoxyisobutyric acids and alkyl esters and salts thereof
IT1222986B (it) * 1987-10-23 1990-09-12 Texcontor Ets Derivati dell'efedrina esterificata aventi attivita' antiulcera prolungata nel tempo
AU612437B2 (en) * 1987-12-14 1991-07-11 Kyowa Hakko Kogyo Co. Ltd. Tricyclic compounds
WO1997001540A1 (en) * 1995-06-29 1997-01-16 Smithkline Beecham Corporation Integrin receptor antagonists
CN1209063A (zh) * 1995-12-29 1999-02-24 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂
JP2002510328A (ja) * 1997-07-25 2002-04-02 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体アンタゴニスト
PE122699A1 (es) * 1997-09-19 2000-02-12 Smithkline Beecham Corp Antagonistas de receptores de vitronectina

Also Published As

Publication number Publication date
JP2001508067A (ja) 2001-06-19
ZA9896B (en) 1998-10-14
TR199901575T2 (xx) 1999-11-22
DE69812602T2 (de) 2004-02-19
MA26462A1 (fr) 2004-12-20
EA199900630A1 (ru) 2000-02-28
NO993350L (no) 1999-09-06
IL130760A0 (en) 2001-01-28
ES2196534T3 (es) 2003-12-16
NO993350D0 (no) 1999-07-07
EP0977735A1 (de) 2000-02-09
HUP0001945A2 (hu) 2000-10-28
BG103548A (en) 2000-11-30
AR010873A1 (es) 2000-07-12
AU5912798A (en) 1998-08-03
EP0977735A4 (de) 2000-04-05
BR9806852A (pt) 2001-08-07
PE44799A1 (es) 1999-06-10
SK92799A3 (en) 1999-12-10
CN1249745A (zh) 2000-04-05
KR20000069941A (ko) 2000-11-25
NZ336560A (en) 2000-11-24
AU729641B2 (en) 2001-02-08
CO4920232A1 (es) 2000-05-29
ATE235467T1 (de) 2003-04-15
US6069158A (en) 2000-05-30
PL334499A1 (en) 2000-02-28
EP0977735B1 (de) 2003-03-26
CA2276738A1 (en) 1998-07-16
DZ2395A1 (fr) 2003-06-04
OA11076A (en) 2003-03-13
US6191304B1 (en) 2001-02-20
AP9901597A0 (en) 1999-09-30
HUP0001945A3 (en) 2001-12-28
ID23168A (id) 2000-03-23
WO1998030542A1 (en) 1998-07-16

Similar Documents

Publication Publication Date Title
DE69812602D1 (de) Antagonisten des vitronectin-rezeptors
ATE312089T1 (de) Vitronektin rezeptor antagonisten
NO965608D0 (no) Vitronectin-reseptor-antagonister
NO983001D0 (no) Vitronectin-reseptor-antagonister
NO983003D0 (no) Vitronectin-reseptor-antagonister
DE69812096D1 (de) Neuropeptid y rezeptorantagonisten
NO983002D0 (no) Vitronectin-reseptor-antagonister
ATE315035T1 (de) Ccr-3-rezeptor-antagonisten
NO20004503D0 (no) Vitronectin-reseptor-antagonister
NO20001407D0 (no) Vitronectin-reseptor-antagonister
NO20001514D0 (no) Vitronectin-reseptor-antagonist
ID24726A (id) Antagonis-antagonis reseptor trombin
NO20001515D0 (no) Vitronektin reseptor-antagonist
ATE381330T1 (de) Il-8 rezeptor-antagonisten
DZ2322A1 (fr) Antagonistes de récepteurs de vitronectine.
ATE277043T1 (de) Vitronectin rezeptor antagonist
ATE303370T1 (de) Il-8 rezeptor antagonisten
NO20021113D0 (no) Vitronectin-reseptor-antagonister
NO20010620D0 (no) Vitronektinreseptor-antagonister
DK1218005T3 (da) Vitronectinreptorantagonister
ZA988562B (en) Vitronectin receptor antagonists
DE69830671D1 (de) Integrin-rezeptor-antagonisten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition